Company intelligence / Profile preview

Valtari Bio

Ownership: Private
Development stage: Other

Overview

Valtari Bio is developing ReST™, a point-of-care blood test designed to enable rapid and unbiased diagnosis and triage of suspected stroke patients. The technology aims to assist clinicians in making faster decisions for patient care in acute settings. No clinical trial results are publicly available as of now.

Therapeutic areas: Neurology
Modalities: DeviceDiagnostic test
Industry: Protein Biomarker Diagnostics

Partnerships

None publicly disclosed.

Beyond the preview

Go deeper on Valtari Bio.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Valtari Bio.

Explore the full profile